James Xue, PhD, MBA, Founder, Chairman and CEO

Dr. Xue is a biopharmaceutical executive with extensive experience in corporate strategy and operations, global business and market development and entrepreneurship.  As the company’s founder, he set the vision of accelerating the development and commercialization of specialty healthcare products for serious and critical medical conditions in China and North Asia.  He was founder and President of CANbridge Consulting LLC which served health care clients in North America and Greater China region and was a Venture Partner at Tullis Health Investors.  Dr. Xue was a senior executive at Genzyme where he spent 10 years in various managerial positions with increasing responsibilities in business development, portfolio strategy, commercial and general management.  During his tenure as the founding General Manager of Genzyme China, Dr Xue developed and implemented Genzyme’s multi-prom business strategy and plan, built a fully-fledged organization and successful business foundation and pioneered orphan drug commercial and societal initiatives including launching the first enzyme replacement therapy and the first orphan drug aid program in the country.  Dr. Xue started his career in biotech industry as a research scientist at Kosan Biosciences in the San Francisco Bay Area.  He holds a B.S. in Pharmaceutical Chemistry from Peking University School of Pharmacy, a Ph.D. in Bioorganic Chemistry from Brown University and a M.B.A. from Darden School of Business, University of Virginia. He received postdoctoral training at University of California San Francisco and executive training from INSEAD and Wharton Business School.

Simon Chunsheng Song, Finance Advisor and Former VP of Finance

Mr. Chunsheng Song has over 20 years of financial transactions, asset management and private equity investment.  He was VP of Finance from 2014-2015 and currently serves as Finance Advisor to CANbridge where played a central role in formulating the company’s financing strategy and oversaw the company finance operations since the inception of the company.  Prior to joining CANbridge, he held senior positions at China Great Wall Finance Company and HEAVEN-SENT Capital Management GROUP, a top Chinese private equity firm.  He managed or engaged in dozens of equity investments in Chinese firms and achieved brilliant returns in various financial markets.  Mr. Song obtained his B.Sc. in International Trade from Shanghai Jiaotong University, and his M.A. in Finance from Central University of Finance and Economics. 


Crystal Ying Xu, MD, Senior Director and Head of Clinical Development

Dr. Xu joined CANbridge as a founding member at the inception of the company.  She has over 30-year experiences in clinical medicine, drug development and medical research.  She led and managed over 15 new drug registration and clinical trial programs in oncology, autoimmune, cardiovascular, renal diseases and metabolic rare genetic diseases.  Two of those drugs have been commercially launched.  Dr. Xu was formerly Director and Head of Medical and Regulatory Affairs at Genzyme China, and Medical Director of RPS Asia Pacific. She also held senior research positions at Huchinson MedPharma and MDS. Prior to entering into industry Dr. Xu was an Attending Physician and clinical researcher in Cardiology at Beijing Fuwai Hospital.  Dr. Xu obtained her Medical Degree from Jilin Medical University and her Masters in Clinical Pharmacology from Peking Union Medical College, Chinese Academe of Medical Sciences.

Chi-Ting Huang, Ph.D.Senior Director of CMC Operations

Dr. Chi-Ting Huang joined CANbridge in 2015 as Senior Director of CMC Operations. She has over 14 years of experience in leading CMC teams for the development of difficult proteins (e.g. Antibody-Drug conjugates, highly glycosylated fusion proteins, TGF-beta proteins). Prior to joining CANbridge, she served as Analytical Director in BioAnalytix and Momenta Pharmaceutical, technical and managerial head in analytical development, formulation and process development at Acceleron.  Dr. Huang also held senior research positions in protein drug development at ImmunoGen and Wyeth Biopharma.  Dr. Huang obtained her B.S. in Chemical Engineering from University of Illinois- Urbana in Chemical Engineering and her Ph.D in Biophysics, Biochemistry and Molecular Biology from University of Minnesota..  

Mark Goldberg, MD , Acting Chief Medical Officer

Dr. Goldberg joined CANbridge as Acting Chief Medical Officer in 2015.  He has been a member of the company’s Advisory Board since 2013.  Dr. Goldberg brings to CANbridge over 30 years of clinical and industry experience as a seasoned oncologist, hematologist and corporate medical/regulatory strategist.  Prior to CANbridge, he was Executive Vice President, Medical and Regulatory Strategy at Synageva BioPharma Corporation. Dr. Goldberg joined Synageva in 2011 from Genzyme Corporation, where he had most recently served as Senior Vice President, Clinical Development and Global Therapeutic Group Head, Oncology and Personalized Genetic Health. While at Genzyme, he played a central role in the development and approval of medicines such as Fabrazyme®, Aldurazyme®, Myozyme®, Lumizyme®, and Mozobil®. Prior to working at Genzyme, he was a full-time staff physician at Brigham and Women's Hospital and Dana Farber Cancer Institute.  He holds appointments at Brigham and Women's Hospital and Dana Farber Cancer Institute and is also an Associate Professor of Medicine (part time) at Harvard Medical School. Dr. Goldberg received his A.B. (magna cum laude) from Harvard College and his M.D. (cum laude) from Harvard Medical School. He holds Board appointments at Immunogen Corporation, Idera Pharmaceuticals, Glycomimetics, aTyr Pharma, Blueprint Medicines, and the American Cancer Society, New England Division. 

Huaizhong Hu, MD, PhD, Vice President of Preclinical Development

Dr. Huaizhong Hu joined CANbridge in July, 2016.  He brings to CANbridge nearly 30 years of combined experiences in industry, academia and clinical medicine.  Prior to CANbridge Dr. Hu spent 10 years at Covance Laboratory and held senior scientific positions as Toxicology Senior Study Director, Immuno-toxicology Lead Scientist at Covance U.S. and most recently Early Development Scientific Director at Covance China.  During his tenure Dr. Hu led or supervised over 200 GLP/non-GLP toxicology or immune-toxicology studies.  Between 2000-2007, Dr. Hu was R&D Director at Renorvar where he led the team and effort that developed biomarkers and diagnostic tests for immunological diseases.  Dr. Hu was a Lee Kuan Yew Research Fellow and Principal Investigator at Department of Microbiology and Faculty of Medicine at National University of Singapore.  He received his Medical Degree from West China University of Medical Sciences and subsequently practiced medicine for 3 years in Clinical Immunology at the First Affiliated University Hospital.  Dr. Hu holds a Ph.D. in T cell immunology from Utrecht University.  He was a Postdoctoral Fellow in immunology and toxicology at the NIH where he successfully cloned and functionally evaluated a recombinant immunotoxin that has been developed and tested in a Phase II clinical trial for skin T cell lymphoma.  He co-authored over 50 publications in peer-reviewed international journals and is an inventor on close to 20 U.S., European and Chinese issued or pending patents.

Cindy Hui Guo ,Senior Director of Regulatory Affairs

Cindy has over 18 years of industry experience in regulatory affairs. Prior to joining CANbridge, Cindy held RA positions with increasing responsibilities at Bayer China, Eli Lilly China, BMS China and Xian Janssen.  Most recently she was Director of regulatory, TA head of immunology, infection disease and cardiovascular and metabolism at Xian Janssen.  She has extensive experience across several therapeutic areas including neuroscience and metabolism. 

Cindy graduated with a Bachelor’s degree in Pharmacology from the Medical school of Fudan University (formerly Shanghai Medical University). Before joining the industry, Cindy worked as an Assistant Researcher at the Institute of Materia Medica (IMM), Chinese Academy of Medical Sciences from 1991 to 1998.

Chris Wei Chen, Director of Human Resources Dep.,

Chris has over 16 years of bio-pharmaceutical experience in HR management in an all-round way, include 11 years of professional experience in Human Resource Management of a US listed company. Prior to joining CANbridge, Chris held several HR management positions at Sinovac Biotech Ltd. (Nasdaq GSM: SVA) , she has many experience for recruiting , and in charge of other important HR Functions. During those 11 years, the staffs members increased from 25, 2002 to more than 600, 2012. Sinovac itself developed from one single company to a Group, several subsidiary companies and JVs. Most recently Chris was the HRD of Huadu Biotech Ltd.  Chris graduated with a Master Degree in Human Resource Management from  RenMin University of China.

本网站由阿里云提供云计算及安全服务 Powered by CloudDream